abrdn plc Buys Shares of 73,476 argenx SE (NASDAQ:ARGX)

abrdn plc bought a new stake in argenx SE (NASDAQ:ARGX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 73,476 shares of the company’s stock, valued at approximately $27,952,000. abrdn plc owned approximately 0.12% of argenx as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC lifted its stake in argenx by 32.2% in the 3rd quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock valued at $743,219,000 after acquiring an additional 368,367 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of argenx by 339.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company’s stock worth $285,925,000 after purchasing an additional 449,151 shares in the last quarter. RTW Investments LP raised its stake in shares of argenx by 5.2% during the 3rd quarter. RTW Investments LP now owns 507,195 shares of the company’s stock worth $249,352,000 after purchasing an additional 25,000 shares in the last quarter. Invesco Ltd. raised its stake in shares of argenx by 377.0% during the 3rd quarter. Invesco Ltd. now owns 430,787 shares of the company’s stock worth $211,788,000 after purchasing an additional 340,482 shares in the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of argenx by 7.4% during the 4th quarter. Federated Hermes Inc. now owns 356,507 shares of the company’s stock worth $135,626,000 after purchasing an additional 24,416 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Up 2.4 %

Shares of ARGX stock opened at $368.75 on Tuesday. argenx SE has a twelve month low of $327.73 and a twelve month high of $550.76. The company has a market cap of $21.91 billion, a P/E ratio of -71.74 and a beta of 0.65. The business has a fifty day simple moving average of $386.95 and a 200 day simple moving average of $419.33.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The business had revenue of $417.84 million for the quarter, compared to the consensus estimate of $378.60 million. During the same quarter in the prior year, the company earned ($0.70) earnings per share. As a group, equities research analysts anticipate that argenx SE will post -2.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Wedbush reiterated an “outperform” rating and set a $521.00 price objective on shares of argenx in a research note on Thursday, April 18th. Wolfe Research assumed coverage on argenx in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. JMP Securities reissued a “market outperform” rating and set a $471.00 target price on shares of argenx in a report on Friday, March 22nd. Robert W. Baird decreased their target price on argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Finally, HC Wainwright reissued a “buy” rating and set a $451.00 target price on shares of argenx in a report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $528.16.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.